• About
  • Subscribe
  • Advertise
  • Contact
Thursday, May 22, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Company updates & acquisitions

Positive results for PolyActiva biodegradable implant for glaucoma

by Staff Writer
November 20, 2023
in Company updates & acquisitions, Eye disease, Glaucoma, News
Reading Time: 2 mins read
A A
PolyActiva implant

The ocular implant is designed to deliver six months of latanoprost and is biodegradable.

Share on FacebookShare on Twitter

Melbourne-based ophthalmology company, PolyActiva, has reported promising clinical trial results for its six-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

The interim results, from an ongoing phase 2a clinical study for the company’s PA5108 ocular implant in subjects with mild to moderate glaucoma, revealed a >20% reduction in intraocular pressure (IOP) at 12 weeks and 26 weeks in the initial cohort.

The ocular implant is designed to deliver six months of latanoprost and is biodegradable, which allows for repeat dosing.

In a further cohort, the implant’s rapid biodegradation profile has also allowed a repeat second dosing for eight out of 17 participants at 21 weeks, providing ongoing, uninterrupted therapy, with no product related adverse effects.

“For ocular implants to ultimately replace daily eye drops for the treatment of glaucoma, they need to be suitable for repeat administration, which has been a principal goal of PolyActiva’s development program. Our phase 2a results indicate we are well placed to meet that objective,” CEO of PolyActiva Ms Vanessa Waddell said.

Treating glaucoma with daily eye drops has been the mainstay of glaucoma therapy, however, between 41-90% of patients do not correctly administer their drops after one year, PolyActiva reported. Ineffective treatment and poor adherence can accelerate loss of sight.

“Sustained drug delivery via an implant could reduce the reliance on daily eye drops and ensure that the correct amount of medicine is delivered consistently, every day,” Waddell said.

“The implants received by these trial participants were present for 26 weeks before they biodegraded, which gives us confidence that our technology will be able to deliver a long-term treatment option for glaucoma patients. We look forward to continuing our development of this product as we plan for confirmatory trials in the US.”

PolyActiva presented its interim phase 2a data at the Eyecelerator Ophthalmic Innovation Conference in San Francisco on 2 November 2023. The company plans to initiate its phase 2b clinical trial in the US, Australia and New Zealand in 2024.

More reading

Dr Elvis Ojaimi first to implant telescopic lens at Epworth Freemasons, Melbourne

Glaukos submits FDA application for iDose TR glaucoma implant

Alcon Hydrus – a MIGS microstent with macro results

Related Posts

Rayner, based in Worthing, UK, has grown its presence and staff numbers in Australia. Images: Rayner.

Rayner – a not-so-little disrupter in the ophthalmic industry

by Rob Mitchell
May 22, 2025

In just a few years, British company Rayner has grown its presence Down Under significantly. The company’s leaders outline the...

CR Labs' ECO7 lens follows the success of its ECO6 product. Image: CR Labs.

CR Labs launches new sustainable lens in thinner format

by Staff Writer
May 22, 2025

CR Labs has launched ECO7, its latest innovation in sustainable lens technology. The company says the new lens builds on...

The Provincial Referral Hospital of Ratanakiri that has received support from Sight For All. Image: Sight For All.

Sight For All raising funds for ophthalmic equipment in new eye clinics   

by Staff Writer
May 22, 2025

Australian not-for-profit Sight For All has teamed up with long-term supporter ZEISS, in a drive to raise funds for much-needed...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited